arterial

Prothrombin Time Comes in Small (CLIA-Waived) Packages

... a target INR of between two and three. To prevent arterial thrombosis in a patient with an artificial heart valve, the INR therapeutic goal may be in the 2.5- to 3.5-range. Several medical manufacturers have gained CLIA-waived status for their PT test devices, allowing rapid assessment in the point of care...

Hemoglobin Testing at the Point of Care

... plastic microcuvette collects the exact amount of arterial or venous blood necessary (10 l). The cuvette cavi...d other sources of turbidity. Capillary, venous or arterial blood samples can be used, so transfusion decisions, EPO dosing and anemia screenings can be perform...

Tight Glycemic Control in the ICU

...titative glucose measurement of capillary, venous, arterial and neonatal whole blood, and yield plasma calibrated results. TELCOR provides connectivity for the 3 systems, and RALS-Plus provides connectivity for Roche and LifeScan. The HemoCue Glucose 201 DM System provides the glucose analyzer, docking sta...

New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk

...y also break and liberate pieces that block distal arterial branches. The final common pathway is insufficien... tissue, paralleling the buildup of cholesterol on arterial walls. The test provides an independent predictor of coronary artery disease. It has been shown to...

Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing

...lood may be taken from a heelstick. In addition to arterial sampling, blood gas panels can be ordered on blood...s quickly as possible after sample collection. For arterial blood gases (ABGs), the collected sample degrades quickly and, if any testing delay is expected, it ...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

...r bleedingassociated with AGGRASTATR occurs at the arterial access site forcardiac catheterization. Fatal bleedings have been reported.AGGRASTATR should be used with caution in patients with plateletcount less than 150,000/mm3, in patients with hemorrhagicretinopathy and in patients in chronic hemodialysis. B...

New Information on the Potential of Plasmin Shared at ISTH Congress

...ecris Biotherapeutics fortreating acute peripheral arterial occlusion. Plasmin is acatheter-delivered, direct and locally acting, fibrin-specificthrombolytic with additional potential applications in other acutebleeding disorders including deep vein thrombosis and ischemicstroke. The plasmin molecule contains...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

...therOx) with vascular thrombosis(particularly with arterial thrombosis) in patients with autoimmunediseases such as systemic lupus erythematosus (SLE) andanti-phospholipid syndrome. The study looked at 113 SLE patients(94 with secondary anti-phospholipid syndrome and 19 without) andconcluded the measurement o...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

...tential acute or chroniccomplications of venous or arterial thrombosis. As with allanticoagulants, the most frequently reported side effect withLovenox(R) is bleeding. Clinical indications for Lovenox(R) mayvary from one country to another. About sanofi-aventis Sanofi-aventis is one of the world's leading p...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

...ive mode of action, ALX-0081 isintended to prevent arterial thrombosis, without interfering withthe desired haemostatis (wound healing) in the patient whichresults in less bleeding complications. Pre-clinical in vivostudies confirmed Ablynx´s belief that ALX-0081 has uniquepotential to set a new standar...

Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event

...ase II developmental compound for theprevention of arterial thrombosis. The results of the Phase IIa andclinic...mistry group discovered DG041 as a meansto prevent arterial thrombosis by inhibiting the activity of EP3.In animal studies and extensive Phase I clinical testin...

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

...ts with criticallimb ischemia (advanced peripheral arterial disease) were evaluatedfor efficacy. The primary endpoints, improvement of rest pain ((VAS(Visual Analog Scale)) or ischemic ulcer size, at 12 weeks postdosing, showed 30.8% improvement in the placebo group and 70.4%improvement in the treatment group...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... is scientificallyrecognized as the first stage of arterial thrombus formation andplays a significant role in ...ve anti-thrombotic treatment at the primary siteof arterial blockage." "We are developing a pipeline of aptamer therapeutics with aproprietary focus in acute c...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

...n patients with TIA or ischaemicstroke of presumed arterial origin. This means that in thesecondary prevention of stroke, stroke patients can benefit fromthe combination treatment with dipyridamole plus ASA independent oftheir underlying risk." The largest trials included in the meta-analysis were the recent...

Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants

...rotocol, including the monitoring of the neonates' arterial bloodoxygen saturation with Masimo SET pulse oximetry, coulddramatically reduce ROP. But some observers questioned how criticalMasimo SET pulse oximetry was to the success of the protocol. Thismulti-center study shows that the accuracy and reliabilit...

Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

...ystem designed todeliver additional support to the arterial wall and with thepotential to reduce late lumen loss (vessel renarrowing) evenfurther." Abbott's everolimus eluting bioabsorbable stent is made ofpolylactic acid, a proven biocompatible material that is commonlyused in medical implants such as dis...

Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension

...n San Francisco, California, May 18-23. "Pulmonary arterial hypertension is a progressive,life-threatening disease for which new therapies are clearlyneeded," said Ronald J. Oudiz, MD, Associate Professor of Medicine,UCLA School of Medicine and Director, Liu Center for PulmonaryHypertension, Los Angeles Biome...

Evidence of Nanoparticles Found in Plaque-Filled Arteries

...l 30. 2007-- Scientific evidenceincreasingly links arterial calcification to the presence ofnanosized particle...in the development ofarteriosclerosis and calcific arterial disease. The study will bepresented during the 2007 Experimental Biology meeting inWashington, D.C.,...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

...ctoris,heart attack, aortic dissection, lower limb arterial obstruction,doubling of serum creatinine, or transition to dialysis. At thestart of the clinical study, as well as during the course of thestudy, blood pressure and heart rate did not differ between thevalsartan regime and the control regime. The ch...

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

...ty and efficacy of the VascularWrap(TM) for use in arterial bypass surgery in patients withperipheral arterial disease (PAD). Dr. Lajos Matyas is presentingthe results at the 2007 European Symposium of Vascular ...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

.... It is used to inhibit clot formation invenous or arterial vessels to avoid potential acute or chroniccomplications of venous or arterial thrombosis such as pulmonaryembolism, myocardial infarction or death of cardiovascular origin.As wit...

Aranesp ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer

...ythropoietic therapies increasethe risk of serious arterial and venous thromboembolic events,including myocardial infarction, stroke, congestive heart failure,and hemodialysis graft occlusion. A rate of hemoglobin rise ofgreater than 1 g/dL over 2 weeks may also contribute to theserisks. To reduce cardiovascu...

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

.... - The risk increases dependent on the number of arterial bedsaffected; with 5% event rate for patients with...vents could beseen in those patients with multiple arterial disease in the USalone over the next 12 months(X) For patients without a history of coronary, cereb...

Actelion Announces Positive Study with Bosentan (Tracleer) in CTEPH

...ous placebo-controlled clinical trials inpulmonary arterial hypertension (PAH). Isaac Kobrin, MD and Head o... Actelion has leveraged its leadership inpulmonary arterial hypertension to conduct the first randomized,placebo-controlled study in a specific form of pulmonar...